The $110 million that Medical Microinstruments Inc. (MMI) recently raised in its series C funding round is testament to its unique position in microsurgery, said Olivier Litzka, a board member at MMI and a partner at Andera Partners. “There are not many companies actually working in that space in robotics,” he told BioWorld.
Alamar Biosciences Inc.’s substantially oversubscribed series C pushed the company’s total funds raised to $250 million. The company closed the first $100 million on Feb. 26 and expects to close an additional $28 million within 30 days. The target for the series C was $100 million. The funds will be used to drive market adoption of its Argo HT system and nucleic acid linked immune-sandwich assay sequencing (NULISAseq) inflammation panel 250 for deep profiling of immune response.
Onera Technologies BV raised €30 million (US$32.7 million) in a series C funding round that will allow the company to accelerate the manufacturing and deployment of its patch-based sleep test system. The funds will also go towards concluding the development of the company’s second-generation polysomnography (PSG) system.
Pattern Bioscience Inc. reeled in $28.7 million in a series C financing led by Illumina Ventures and Omnimed Capital. The money will be used to complete development of its rapid phenotypic test platform for infectious diseases, conduct clinical validation studies and submit the platform and Pattern’s initial test, for pneumonia, for U.S. FDA review.
Beijing Surgerii Technology Co. Ltd. completed a series C3 round to support the development of its robotic system for single-port laparoscopic surgery.
Shenzhen Core Medical Technology Co. Ltd. completed a series C round to speed up the development of its left ventricular assist devices (LVAD) for heart failure.
Perspectum Diagnostics Ltd. reported the first close at $36 million of its series C round, with the majority of the new money due to be invested in expanding U.S. uptake of its Livermultiscan diagnostic for assessing and monitoring chronic liver disease.
Qitan Technology Co. Ltd. has raised ¥700 million (US$104 million) in a series C round led by Meituan Inc. to improve its nanopore sequencing devices and expand its market.
Osler Diagnostics Ltd. has raised $85 million in a series C round, as it embarks on clinical testing to secure regulatory approvals for its portable central lab quality diagnostics system.
Genetesis Inc. nearly doubled its total funds raised to $40 million with a $17.5 million series C financing round to support new clinical trials and commercialize its magnetocardiography system, Cardioflux. Mithril Capital led the round with participation from another new investor, Cercano Management, as well existing investors Jobs Ohio Growth Capital, Ohio Innovation Fund and Cincytech.
